BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23053582)

  • 1. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up.
    Takeda N; Isu K; Hiraga H; Shinohara N; Minami A; Kamata H
    J Orthop Sci; 2012 Nov; 17(6):770-4. PubMed ID: 23053582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
    Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
    BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
    Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
    Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
    Lipton A; Zheng M; Seaman J
    Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of radiotherapy and bisphosphonate on bone metastases from renal cell carcinoma].
    Okuda H; Sugiura H; Yamada K; Hayashi N; Soga N; Ogura Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(11):1497-501. PubMed ID: 24231702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
    Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
    Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    Saad F; Lipton A
    BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
    Lipton A; Colombo-Berra A; Bukowski RM; Rosen L; Zheng M; Urbanowitz G
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
    Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
    Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
    Saad F; Chen YM; Gleason DM; Chin J
    Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
    Saad F; Eastham JA
    Semin Oncol; 2010 Jun; 37 Suppl 1():S38-44. PubMed ID: 20682371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
    Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
    Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma.
    Harada H; Shikama N; Wada H; Uchida N; Nozaki M; Hayakawa K; Yamada K; Nagakura H; Ogawa H; Miyazawa K; Katagiri H; Nakamura N
    Jpn J Clin Oncol; 2021 Jan; 51(1):100-105. PubMed ID: 32869095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
    J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
    Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.